IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Beta Drugs Ltd.
Issue Open Date 29-Sep-17  
Issue Closing Date 04-Oct-17  
Application Money 100  
Allotment Money  
Price Band 85 -  
Minimium Application No. 1600  
Issue Size (Shares) 2296000  
Market Lot 1.00  
Objective
OBJECT OF THE ISSUERequirement of FundsThe proceeds of the Issue, after deducting Issue related expenses, are estimated to be 1951.60 lakhs(the Net Proceeds)We intend to utilize the Net Proceeds towards the following objects:1. Purchase of new plant and machinery and upgradation of our existing plant and machinery.2. Civil Construction work at existing manufacturing unit.3. To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operationScheme certificate4. Working Capital requirements.5. General Corporate Purpose.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors     32235200   NA  
Qualified Institutional Buyers     316800   NA  
Retail Individual Investors     8664000   NA  
Business Description
OVERVIEWBeta Drugs Limited is a part of Adley Group. Adley Group was founded in the year 1985, by our promoterVijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products inIndia. Beta Drugs Limited is , pharmaceutic
more...
Promoter's Holding
Total Share Capital    
Offered to Public    
Promoter's Holding (Pre-Issue)    
Promoter's Holding (Post-Issue)    
Address
Village Nandpur
Lodhimajra Road
Distt Solan
Baddi ,
Himachal Pradesh ,
174101
Phone: 01795-236196
Email: cs@betadrugslimited.com
Website: www.betadrugslimited.com
Registrar
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
NSE
Lead Manager
Pantomath Capital Advisors Pvt Ltd.
Promoters
Vijay Kumar Batra
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Awareness & Information | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.